HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill Steering Hemp In Supplements To NDI Notification Pathway Introduced For Third Time

Executive Summary

Virginia Republican Morgan Griffith has same message for FDA he’s previously stated about hemp ingredients. Agency “has dragged its feet in properly regulating CBD and hemp-derived products on the market, creating confusion about its legal uses,” he says.

You may also be interested in...



Food In Capitol Hill's Lawful Hemp Recipe, But CBD, Delta-8 On FDA Unsafe Food Ingredients Menu

All legislation introduced in Congress on establishing hemp as lawful dietary ingredient also would extend change to food ingredients. Two hemp derivatives among 12 ingredients on FDA’s first list of food ingredients unsafe for use in food.

US Hemp Industry Group Rings Alarm With Congress About FDA’s Safety Conclusions

US Hemp Roundtable general counsel cautions congressional leaders about “agency’s misguided use of incomplete safety data as the basis for its continued refusal to regulate CBD as a dietary supplement or food additive.”

Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements

Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel